Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.8801
-0.0382 (-4.16%)
At close: Apr 24, 2026, 4:00 PM EDT
0.8899
+0.0098 (1.11%)
After-hours: Apr 24, 2026, 7:39 PM EDT
Immunic Employees
Immunic had 92 employees as of December 31, 2025. The number of employees increased by 1 or 1.10% compared to the previous year.
Employees
92
Change
1
Growth
1.10%
Revenue / Employee
n/a
Profits / Employee
-$1,056,217
Market Cap
114.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Sep 30, 2025 | 90 | 5 | 5.88% |
| Jun 30, 2025 | 90 | 5 | 5.88% |
| Mar 31, 2025 | 90 | 10 | 12.50% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Sep 30, 2024 | 85 | 5 | 6.25% |
| Jun 30, 2024 | 85 | 10 | 13.33% |
| Mar 31, 2024 | 80 | 7 | 9.59% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Sep 30, 2023 | 80 | 15 | 23.08% |
| Jun 30, 2023 | 75 | 15 | 25.00% |
| Mar 31, 2023 | 73 | 18 | 32.73% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Sep 30, 2022 | 65 | 13 | 25.00% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 55 | 15 | 37.50% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Sep 30, 2021 | 52 | 24 | 85.71% |
| Jun 30, 2021 | 45 | - | - |
| Mar 31, 2021 | 40 | 14 | 53.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| Vivani Medical | 42 |
| Aardvark Therapeutics | 40 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 29 |
IMUX News
- 2 days ago - Immunic, Inc. Announces 1-for-10 Reverse Stock Split - PRNewsWire
- 8 days ago - Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says - Benzinga
- 16 days ago - Immunic to Participate in Scientific and Medical Conferences in April - PRNewsWire
- 24 days ago - Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 25 days ago - Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - PRNewsWire
- 5 weeks ago - Immunic Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 6 weeks ago - Immunic Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PRNewsWire